## MTD: Mettler-Toledo International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.8% below STRENGTH zone (4.0-10.0%); PEG 5.87 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1341.22)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Mackenzie Financial Corp Sells 776 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251205T120837 | Neutral | Relevance: 100%
- Mackenzie Financial Corp reduced its stake in Mettler-Toledo International, Inc. by selling 776 shares, bringing its total holdings to 2,442 shares valued at $2,869,000. Other institutional investors also adjusted their positions, and analysts have issued various ratings and price targets for the medical instruments supplier. Insiders have also sold a significant number of shares recently.

**2. Epoch Investment Partners Inc. Decreases Stock Position in Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251205T101215 | Neutral | Relevance: 100%
- Epoch Investment Partners Inc. decreased its stake in Mettler-Toledo International, Inc. by 0.7% in the second quarter. Meanwhile, several other institutional investors adjusted their positions, with Vanguard Group Inc. significantly increasing its holdings. Company insiders, including the CFO and CEO, also sold shares, totaling approximately $28.68 million in sales over the last ninety days.

**3. Arrowstreet Capital Limited Partnership Acquires 10,910 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251204T083213 | Somewhat-Bullish | Relevance: 100%
- Arrowstreet Capital Limited Partnership increased its stake in Mettler-Toledo International, Inc. by 19% in Q2, acquiring 10,910 additional shares, bringing its total holdings to 68,259 shares valued at approximately $80.2 million. This move coincides with several brokers raising price targets for Mettler-Toledo, though the consensus remains a "Hold" rating with an average price target of $1,419.55. The company recently surpassed quarterly earnings and revenue expectations and provided positive FY2025 guidance.

**4. Mettler-Toledo International (NYSE:MTD) Earns Equal Weight Rating from Analysts at Morgan Stanley**
- Source: MarketBeat | 20251203T141534 | Neutral | Relevance: 100%
- Morgan Stanley initiated coverage on Mettler-Toledo International (NYSE:MTD) with an "Equal Weight" rating and a $1,550 price target. The company recently beat Q3 earnings estimates and issued strong FY2025 guidance, but has seen significant insider selling. Other analysts hold a "Hold" consensus rating with various price target adjustments.

**5. New York State Common Retirement Fund Buys 3,015 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251203T123505 | Somewhat-Bullish | Relevance: 100%
- The New York State Common Retirement Fund increased its stake in Mettler-Toledo International, Inc. (NYSE:MTD) by 19.3%, acquiring 3,015 additional shares to hold a total of 18,660 shares worth $21.92 million. This move is part of broader institutional investor activity, with major firms like Vanguard and BNY Mellon also boosting their positions, resulting in institutional investors owning approximately 95.07% of the stock. Mettler-Toledo recently surpassed Q3 earnings expectations, reporting an EPS of $11.15 against an anticipated $10.62 and revenue of $1.03 billion, and has provided strong FY2025 EPS guidance, although analysts maintain a consensus "Hold" rating with a target price of $1,406.50.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $1550 | $0 | 0% |
| 2025-11-10 | Citigroup | $1700 | $1600 | +6% |
| 2025-11-10 | Barclays | $1600 | $1350 | +19% |
| 2025-11-10 | Wells Fargo | $1400 | $1200 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |
| 2025-11-10 | Citigroup | main | Buy |
| 2025-11-10 | Barclays | main | Overweight |
| 2025-11-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 18 ($1.28M) |
| Sells | 6 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+1.4%)
- Blackrock Inc.: 9.2% (-3.1%)
- State Street Corpora: 4.7% (-0.5%)
- Capital Internationa: 4.2% (+1.2%)
- Bank Of New York Mel: 4.0% (-9.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.9% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 5.9x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 5.87 signals overvaluation risk, limited margin of safety. Forward P/E 30.9x stretched relative to 8% growth. Quality metrics strong (ROE 30%, ROA 20%, margin 21%). Analyst sentiment positive (4 raises, avg +13%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $29.3B |
| Beta | 1.40 |
| 52W Range | $946.69 - $1525.17 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 5.87 |
| Forward P/E | 30.9 |
| Current P/E | 33.5 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.1% to -3.8% (-4.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.8pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.14x) but short-term weakness (below SMA20). MACD histogram bearish (-6.97), momentum weakening. RSI neutral at 48. OFD pattern: -SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.81% (CS: 19) | Weak |
| RSI_14 | 47.7 | Neutral |
| MACD Histogram | -6.97 | Bearish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 1.023x | Above |
| vs SMA200 | 1.139x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1414.86
- **Stop Loss:** $1341.22 (5.2% risk)
- **Target:** $1488.50 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 6
- **Position Value:** $8,489.16
- **Portfolio %:** 8.49%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-05 (Est: $12.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $10.66 | $11.15 | +4.6% |
| 2025Q2 | $9.60 | $10.09 | +5.1% |
| 2025Q1 | $7.88 | $8.19 | +3.9% |
| 2024Q4 | $11.72 | $12.41 | +5.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*